Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025)

Iridex (IRIX) posted quarterly Asset Writedowns and Impairment of $800000.0 for Q3 2025, up 892.08% quarter-over-quarter from -$101000.0 in Q1 2022.

Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends

Iridex's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $800000.0 for Q3 2025.

In Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $800000.0; the TTM figure through Jan 2026 stood at $800000.0 (up 1350.0% YoY), while the FY2026 annual figure was $823000.0, changed N/A from the prior year.
Asset Writedowns and Impairment for Q3 2025 stood at $800000.0, up from -$101000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $800000.0 in Q3 2025, with the low at -$101000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.46 Bn	193.86 Bn	7.27 Bn
2	Stryker	127.41 Bn	123.93 Bn	4.50 Bn
3	Medtronic	118.87 Bn	109.65 Bn	6.41 Bn
4	Boston Scientific	73.47 Bn	72.93 Bn	3.85 Bn
5	Edwards Lifesciences	51.95 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.30 Bn	32.35 Bn	830.00 Mn
7	GE HealthCare Technologies	33.76 Bn	31.65 Bn	2.18 Bn
8	Koninklijke Philips	26.35 Bn	23.02 Bn	4.55 Bn
9	Steris	23.04 Bn	22.55 Bn	684.20 Mn
10	Iridex	13.34 Mn	8.66 Mn	4.30 Mn

Download Data